The AIM team will be exhibiting at the 2017 ASCB | EMBO Meeting in Philadelphia. The meeting will take place from December 2-6th, while the exhibition will be from 930am-4pm December 3-5th.
See you at:
Pennsylvania Convention Center,
1101 Arch St,
Philadelphia, PA 19107 USA.
Please email us at firstname.lastname@example.org if you would like to schedule a meeting.
Two Cancer Discovery papers feature a novel ex vivo immune checkpoint assay developed with AIM chips
Researchers at the Dana-Farber Cancer Institute and MIT have developed a novel ex vivo assay (above) to profile the PD-1 blockade, making it possible to interrogate the tumor immune microenvironment, develop novel therapeutic combinations, and facilitate precision immuno-oncology efforts. The assay is detailed by Jenkins et al in “Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids“, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0833
The ex vivo organotypic tumor spheroid culture system was utilised by Deng et al to show that CDK4/6 inhibition augments the response to PD-1 blockade. The effect was validated in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. The results are detailed in “CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation”, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0915
Dana-Farber Cancer Institute news release (click here)
* Update 5th Sep 2018
Follow up publication: *3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP... Jenkins RW. Lab on a Chip, 2018, DOI: 10.1039/C8LC00322J